Rigel Pharmaceuticals Inc
NASDAQ:RIGL

Watchlist Manager
Rigel Pharmaceuticals Inc Logo
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Watchlist
Price: 20.55 USD -2.47% Market Closed
Market Cap: 367.2m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+67%
Revenue
Forecast
+14%
Operating Income
Forecast
+43%
Net Income
Forecast
+55%

Wall Street
Price Targets

RIGL Price Targets Summary
Rigel Pharmaceuticals Inc

Wall Street analysts forecast RIGL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RIGL is 34.42 USD with a low forecast of 20.65 USD and a high forecast of 59.85 USD.

RIGL Lowest Forecast
Wall Street Target
20.65 USD
1% Upside
RIGL Average Forecast
Wall Street Target
34.42 USD
67% Upside
RIGL Highest Forecast
Wall Street Target
59.85 USD
191% Upside
Lowest
Price Target
20.65 USD
1% Upside
Average
Price Target
34.42 USD
67% Upside
Highest
Price Target
59.85 USD
191% Upside
Rigel Pharmaceuticals Inc Competitors:
Price Targets
D
CRVO
Diffusion Pharmaceuticals Inc
96% Upside
OXB
Oxford BioMedica PLC
39% Upside
4587
PeptiDream Inc
114% Upside
S
096530
Seegene Inc
50% Upside
D
CRVO
Diffusion Pharmaceuticals Inc
96% Upside
OXB
Oxford BioMedica PLC
39% Upside
4587
PeptiDream Inc
114% Upside
S
096530
Seegene Inc
50% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
26% Upside
ZYME
Zymeworks Inc
60% Upside
BCRX
BioCryst Pharmaceuticals Inc
108% Upside
ARGX
argenx SE
36% Upside

Revenue
Forecast

Revenue Estimate
Rigel Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Rigel Pharmaceuticals Inc's revenue is 31%. The projected CAGR for the next 3 years is 14%.

31%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Rigel Pharmaceuticals Inc

The compound annual growth rate of Rigel Pharmaceuticals Inc's operating income for the next 3 years is 43%.

N/A
Past Growth
43%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Rigel Pharmaceuticals Inc

The compound annual growth rate of Rigel Pharmaceuticals Inc's net income for the next 3 years is 55%.

N/A
Past Growth
55%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
RIGL intrinsic value, competitors valuation, and company profile.
DCF Valuation
RIGL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RIGL stock valuation using valuation multiples.
Wall Street Estimates
RIGL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RIGL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RIGL's stock price target?
Price Target
34.42 USD

According to Wall Street analysts, the average 1-year price target for RIGL is 34.42 USD with a low forecast of 20.65 USD and a high forecast of 59.85 USD.

What is Rigel Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Rigel Pharmaceuticals Inc's revenue is 31%. The projected CAGR for the next 3 years is 14%.

What is Rigel Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
43%

The compound annual growth rate of Rigel Pharmaceuticals Inc's operating income for the next 3 years is 43%.

What is Rigel Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
55%

The compound annual growth rate of Rigel Pharmaceuticals Inc's net income for the next 3 years is 55%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 270,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.